Analytics cookies help us understand what works in the catalog. Accept all, reject non-essential ones, or choose categories below. Privacy policy
The body's own peptide, cut from thymosin beta-4: it is studied as a natural anti-fibrotic signal for the heart and kidneys. Curiously, common blood-pressure medicines raise its level fivefold.
Size: 10 mg
No published analyses yet.
Research, properties and limitations
AI can make mistakes
Titration schedule · reference
The information below is provided from public sources for reference only. It is not advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 200–500 mcg per day, subcutaneous | Starting dose |
| Main regimen | 0.5–1 mg per day, subcutaneous | Increase if needed |
| Upper reference | up to ~2 mg per day | Maximum in this schedule |
Research overview · reference
Below is a short summary of what the authors of published studies reported. It is not medical advice or instructions for use; products are intended for laboratory research only and not for human consumption.
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Prevention of hematopoietic stem cells entering DNA synthesis | Mouse hematopoietic stem cells, after cytarabine | An experimental effect on hematopoiesis; the abstract gives neither the administration route nor clinical reaction frequencies | [1] |
FAQ
Find answers to questions about AC-SDKP and related materials.
Ac-SDKP is an endogenous tetrapeptide: the first four amino acids of thymosin beta-4, which the enzyme prolyl oligopeptidase cuts off the "parent" molecule. It is not made by a separate gene — the body produces it from an existing protein.
Source / documentationAs a natural anti-fibrotic signal — in heart, kidney and lung models: fibrosis, the replacement of working tissue with scar tissue, is the common end-stage of many chronic diseases of these organs. Details are in the Ac-SDKP monograph in our wiki.
Source / documentationAn unusual trait: no receptor of its own has ever been found for Ac-SDKP. Instead it is defined by its destroying enzyme — ACE (the very target of popular blood-pressure medicines): Ac-SDKP is the natural specific substrate of ACE’s N-domain, which is why ACE inhibitors raise the peptide’s plasma level roughly fivefold.
Source / documentationThymosin beta-4 is the 43-amino-acid "parent" molecule, looked at for healing and tissue repair. Ac-SDKP is its short fragment with its own, anti-fibrotic research line; data for one does not automatically transfer to the other.
Source / documentationHonestly: no human regimens are established — our dosing guide on this page extrapolates preclinical work rather than a human protocol. Reference points are there.
Source / documentationThere is no human safety data — the research is preclinical, so an honest list of side effects cannot be compiled. A full review of the known data is in the Ac-SDKP monograph in our wiki.
Source / documentationYou can buy Ac-SDKP right on this page of our store: current prices and stock are shown in the product card. We deliver across Ukraine with Nova Poshta — to a branch, a parcel locker, or by courier. Payment is by card, by crypto (with a 5% discount), or on delivery. Every vial ships with the certificate of analysis (COA) for its exact batch.
Source / documentationShare your experience
No reviews yet. Tell others what you think of this product.
Ac-SDKP is an endogenous tetrapeptide: the first four amino acids of thymosin beta-4, which the enzyme prolyl oligopeptidase cuts off the "parent" molecule. It is not made by a separate gene — the body produces it from an existing protein.
An unusual trait: no receptor of its own has ever been found for Ac-SDKP. Instead it is defined by its destroying enzyme — ACE (the very target of popular blood-pressure medicines): Ac-SDKP is the natural specific substrate of ACE's N-domain, which is why ACE inhibitors raise the peptide's plasma level roughly fivefold. Research looks at Ac-SDKP as an anti-fibrotic signal — in heart, kidney and lung models. Details are in the Ac-SDKP monograph.
Honestly about the limits: no human regimens are established — our dosing guide extrapolates preclinical work rather than a human protocol. The full line is in the anti-fibrosis category.
Every batch is purity-tested by HPLC, and the certificate of analysis (COA) for your exact batch is in our COA archive. Keep the dry powder in a dry, dark place at a low temperature, and the dissolved solution in the refrigerator.